RayKnowChina Research Map
Shortlist0

TianjinPeking Union Medical College / Chinese Academy of Medical Sciences

Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC

中国医学科学院血液病医院(血液学研究所)

Listed for 12 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Neuroblastoma神经母细胞瘤1 paper led
  2. Multiple myeloma多发性骨髓瘤47 papers led28 open trials led
  3. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病13 papers led12 open trials led
  4. Aplastic anaemia再生障碍性贫血48 papers led9 open trials led
  5. Beta thalassaemiaβ 地中海贫血1 paper led
  6. Haemophilia A血友病 A25 papers led5 open trials led
  7. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  8. Fanconi anaemia范可尼贫血3 papers led
  9. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  10. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  11. Gaucher disease戈谢病0 papers led
  12. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Ewing sarcoma, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, IgA nephropathy, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

11 hospitals in Tianjin for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 47 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 2.8%.

Papers led
47
2021–2025
Trials led
42
any status, ClinicalTrials.gov
Open trials led
28
recruiting or about to
Open trials as a site
24
led by another institution
Papers led per year
2021: 0020212022: 8820222023: 131320232024: 171720242025: 772025

5 hospitals in Tianjin for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 52

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07322159

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  2. Recruiting
    MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07409454

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  3. Recruiting
    CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07585760

    Age 18 years to 80 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  4. Recruiting
    CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07652905

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  5. Recruiting
    BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06793449

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  6. Recruiting
    Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06793475

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  7. Recruiting
    BCMA CAR-T for Dynamic High-risk Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06880393

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  8. Recruiting
    A Study of CT0596 in Plasma Cell Leukemia
    Phase
    Early phase 1
    Started
    2025-06
    Registry
    NCT06988059

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  9. Recruiting
    A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07106671

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  10. Recruiting
    ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07106684

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  11. Recruiting
    ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07106710

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  12. Recruiting
    MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07106736

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  13. Recruiting
    Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT07109323

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  14. Recruiting
    Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT07169500

    Age 18 years to 50 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  15. Recruiting
    CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-03
    Registry
    NCT07249073

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  16. Recruiting
    BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06745687

    Age 18 years to 78 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  17. Recruiting
    A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
    Phase
    Phase 2
    Started
    2023-08
    Registry
    NCT05979363

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  18. Recruiting
    DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06158269

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  19. Recruiting
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    Phase
    Phase 2
    Started
    2022-04
    Registry
    NCT05294055

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou

  20. Recruiting
    ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
    Phase
    Phase 1/Phase 2
    Started
    2022-07
    Registry
    NCT05632380

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  21. Recruiting
    National Longitudinal Cohort of Hematological Diseases
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT04645199

    Age not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  22. Not yet recruiting
    A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07399444

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesNanchang, Tianjin, Wuhan, Xuzhou, Zhengzhou

  23. Not yet recruiting
    A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07539233

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  24. Not yet recruiting
    Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
    Phase
    Phase 1/Phase 2
    Started
    2026-08
    Registry
    NCT07687004

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  25. Not yet recruiting
    A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07726160

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  26. Not yet recruiting
    HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07811986

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  27. Not yet recruiting
    CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07830485

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  28. Not yet recruiting
    QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
    Phase
    Phase 2
    Started
    2026-12
    Registry
    NCT07903636

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  29. Recruiting
    A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
    Phase
    Phase 1
    Started
    2026-02
    Registry
    NCT07409246

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Tianjin

  30. Recruiting
    A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07452198

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  31. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  32. Recruiting
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07529782

    Age Not stated to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin

  33. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  34. Recruiting
    A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07579234

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  35. Recruiting
    Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07620275

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General Hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  36. Recruiting
    GR1803 Injection in Patients With RRMM
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06952075

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  37. Recruiting
    Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07018050

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  38. Recruiting
    LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07100067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan

  39. Recruiting
    A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07312188

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  40. Recruiting
    A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
    Phase
    Phase 1/Phase 2
    Started
    2024-02
    Registry
    NCT06232096

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  41. Recruiting
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-05
    Registry
    NCT06375044

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou

  42. Recruiting
    Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT07028970

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Tianjin, Wuhan, Zhengzhou

  43. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  44. Recruiting
    A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Registry
    NCT05521802

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  45. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  46. Recruiting
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05623020

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  47. Recruiting
    A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2021-02
    Registry
    NCT04634552

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Suzhou, Tianjin, Xi'an

  48. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  49. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  50. Not yet recruiting
    Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07910903

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  51. Not yet recruiting
    Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07181239

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  52. Not yet recruiting
    A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-08
    Registry
    NCT06500507

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskRelapse & resistanceStem cell transplant
Papers it led47
  1. Harnessing Targeted Photodynamic Therapy to Synergistically Activate T Cell and NK Cell Responses in Multiple Myeloma.2026Advanced materials (Deerfield Beach, Fla.)
  2. Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Prodigiosin inhibits proliferation and induces apoptosis through influencing amino acid metabolism in multiple myeloma.2025Bioorganic chemistry
  4. Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma.2025Blood
  5. Correlation between the expression of soluble BCMA and short-term/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma.2025Cell transplantationFree full text
  6. Identification and transformation of novel targets for immunotherapy in multiple myeloma.2025Chinese medical journalFree full text
  7. Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing.2025Haematologica
  8. Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation.2025Science translational medicine
  9. Raman spectroscopy of dried serum for the detection of rapid noninvasive multiple myeloma.2025Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  10. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.2024American journal of hematologyFree full text
  11. T(11;14) with multiple myeloma: Standard risk survival but slow and poor response.2024Annals of hematology
  12. Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM).2024Annals of hematology
  13. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.2024Blood advancesFree full text
  14. Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.2024Cancer
  15. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma.2024Cell metabolism
  16. Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing.2024Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
  17. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).2024Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
  18. CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy.2024EBioMedicineFree full text
  19. B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma.2024ESC heart failureFree full text
  20. DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.2024Frontiers in immunologyFree full text
  21. LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.2024HaematologicaFree full text
  22. Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.2024Haematologica
  23. Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report.2024Journal for immunotherapy of cancerFree full text
  24. Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma.2024Leukemia
  25. Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma.2024LeukemiaFree full text
  26. Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma.2024Scientific reportsFree full text
  27. Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation.2023Annals of hematologyFree full text
  28. Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase.2023British journal of haematology
  29. Immunotherapy for multiple myeloma: new chances and hope.2023Cancer biology & medicineFree full text
  30. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.2023Cancer biology & medicineFree full text
  31. CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression.2023Cancer immunology research
  32. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.2023Cancer research communicationsFree full text
  33. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.2023Chinese medical journalFree full text
  34. Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma.2023Chinese medical journalFree full text
  35. Multiple myeloma-derived miR-27b-3p facilitates tumour progression via promoting tumour cell proliferation and immunosuppressive microenvironment.2023Clinical and translational medicineFree full text
  36. Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.2023Clinical lymphoma, myeloma & leukemiaRCT
  37. The age-dependent changes in risk weights of the prognostic factors for multiple myeloma.2023Hematology (Amsterdam, Netherlands)
  38. The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma.2023Hematology (Amsterdam, Netherlands)
  39. Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma.2023Nature communicationsFree full text
  40. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.2022BMC medicineFree full text
  41. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH.2022Blood advancesFree full text
  42. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.2022EBioMedicineFree full text
  43. Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma.2022Frontiers in immunologyFree full text
  44. Comparative analysis of three serum-free light-chain detection systems in the diagnosis of multiple myeloma.2022International journal of laboratory hematology
  45. A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma.2022Journal of immunotherapy (Hagerstown, Md. : 1997)
  46. The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.2022Leukemia & lymphoma
  47. Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance.2022Nature communicationsFree full text
Chinese-language papers (not in the count)17
  1. [Interpretation of risk stratification in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  2. [Progress in risk stratification and treatment of high-risk smoldering multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  3. [Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  4. [Clinical analysis of 14 patients aged ≤ 50 years with high-risk multiple myeloma treated with allogeneic hematopoietic stem cell transplantation].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  5. [Establishment of Patient-Derived Xenograft (PDX) Zebrafish Model of Multiple Myeloma and Its Application in Drug Screening].2023Zhongguo shi yan xue ye xue za zhi
  6. [Safety and feasibility of 120 min rapid infusion regimen of daratumumab in patients with multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  7. [Efficacy and safety of autologous hematopoietic stem cell transplantation pretreated with Melphalan hydrochloride for injection in the treatment of 125 cases of multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  8. [The Clinical Significance of Oligoclonal Bands in Patient with Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  9. [Clinical characteristics and prognosis of 46 patients with macrofocal multiple myeloma].2022Zhonghua nei ke za zhi
  10. [Diagnostic and prognostic value of serum miR-19a-3p in patients with multiple myeloma].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  11. [Establishment and comparison of three human multiple myeloma cell line transplantation models in mice].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  12. [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone].2022Zhonghua yi xue za zhi
  13. [Cdc37 Expression in Multiple Myeloma and Its Role in Cell Proliferation].2021Zhongguo shi yan xue ye xue za zhi
  14. [Two Serum Free Light Chain Detection Systems in the Diagnosis of Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
  15. [Clinical Analysis of Patients with MGUS, Primary Light Chain Amyloidosis, Multiple Myeloma or Multiple Myeloma with Concurrent Amyloidosis].2021Zhongguo shi yan xue ye xue za zhi
  16. [Immunoglobulin M multiple myeloma: a six-case report and literature review].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  17. [Progress in clonal evolution of multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status92
  1. A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.Not yet recruitingNCT07539233Lead sponsorEarly phase 1Start 2026-04
  2. CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal ImpairmentRecruitingNCT07585760Lead sponsorPhase 2Start 2026-09
  3. MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple MyelomaRecruitingNCT07409454Lead sponsorPhase 2Start 2026-07
  4. CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingNCT07652905Lead sponsorPhase 2Start 2026-09
  5. QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary DiseaseNot yet recruitingNCT07903636Lead sponsorPhase 2Start 2026-12
  6. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)Not yet recruitingNCT07399444Lead sponsorEarly phase 1Start 2026-01
  7. IASO206 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07322159Lead sponsorEarly phase 1Start 2026-01
  8. CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07830485Lead sponsorPhase 2Start 2026-10
  9. Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic StratificationNot yet recruitingNCT07687004Lead sponsorPhase 1/Phase 2Start 2026-08
  10. HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary DiseaseNot yet recruitingNCT07811986Lead sponsorPhase 2Start 2026-09
  11. A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07726160Lead sponsorPhase 1Start 2026-07
  12. ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell LeukemiaRecruitingNCT07106684Lead sponsorPhase 2Start 2025-08
  13. CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple MyelomaRecruitingNCT07249073Lead sponsorEarly phase 1Start 2025-03
  14. Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MMRecruitingNCT07109323Lead sponsorPhase 1/Phase 2Start 2025-03
  15. A Study of CT0596 in Plasma Cell LeukemiaRecruitingNCT06988059Lead sponsorEarly phase 1Start 2025-06
  16. MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple MyelomaRecruitingNCT07106736Lead sponsorPhase 2Start 2025-08
  17. ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple MyelomaRecruitingNCT07106710Lead sponsorPhase 2Start 2025-08
  18. BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple MyelomaRecruitingNCT06793449Lead sponsorPhase 2Start 2025-02
  19. Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma PatientsRecruitingNCT07169500Lead sponsorPhase 1/Phase 2Start 2025-03
  20. Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary DiseaseRecruitingNCT06793475Lead sponsorN/AStart 2025-04
  21. A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple MyelomaRecruitingNCT07106671Lead sponsorPhase 2Start 2025-08
  22. BCMA CAR-T for Dynamic High-risk Multiple MyelomaRecruitingNCT06880393Lead sponsorPhase 2Start 2025-03
  23. BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple MyelomaRecruitingNCT06745687Lead sponsorN/AStart 2024-12
  24. DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple MyelomaRecruitingNCT06158269Lead sponsorPhase 2Start 2023-12
  25. A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell LeukemiaRecruitingNCT05979363Lead sponsorPhase 2Start 2023-08
  26. Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and LymphomaRecruitingNCT05294055Lead sponsorPhase 2Start 2022-04
  27. ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)RecruitingNCT05632380Lead sponsorPhase 1/Phase 2Start 2022-07
  28. National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199Lead sponsorStart 2020-12
  29. A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple MyelomaActive, not recruitingNCT05860036Lead sponsorPhase 2Start 2023-04
  30. YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple MyelomaStatus unknownNCT05913804Lead sponsorPhase 1Start 2023-06
  31. Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple MyelomaStatus unknownNCT06302699Lead sponsorStart 2023-05
  32. A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 AbnormalitiesActive, not recruitingNCT05850286Lead sponsorPhase 2Start 2023-04
  33. A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell LeukemiaActive, not recruitingNCT05870917Lead sponsorPhase 2Start 2023-05
  34. BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCTWithdrawnNCT05846737Lead sponsorPhase 2Start 2023-05
  35. CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT07809594Lead sponsorPhase 1Start 2023-07
  36. ctDNA Methylation Sequencing for MyelomaStatus unknownNCT05578625Lead sponsorStart 2022-08
  37. Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple MyelomaStatus unknownNCT05549973Lead sponsorPhase 1Start 2022-09
  38. Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple MyelomaStatus unknownNCT05536700Lead sponsorStart 2021-12
  39. A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaCompletedNCT04322292Lead sponsorPhase 1Start 2019-09
  40. a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma PatientsStatus unknownNCT04008888Lead sponsorN/AStart 2018-01
  41. Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MMStatus unknownNCT05749133Lead (inferred)Phase 1/Phase 2Start 2023-04
  42. Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple MyelomaStatus unknownNCT05693012Lead (inferred)Start 2022-08
  43. Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT07910903Study sitePhase 3Start 2026-12
  44. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  45. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  46. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07529782Study sitePhase 1Start 2026-03
  47. Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMARecruitingNCT07620275Study sitePhase 1Start 2026-09
  48. A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07579234Study sitePhase 3Start 2026-01
  49. A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07452198Study sitePhase 3Start 2026-03
  50. A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)RecruitingNCT07409246Study sitePhase 1Start 2026-02
  51. Study of CM336 in Relapsed or Refractory Multiple Myeloma PatientsNot yet recruitingNCT07181239Study sitePhase 3Start 2025-09
  52. LCAR-F33S in Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT07100067Study siteN/AStart 2025-09
  53. Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple MyelomaRecruitingNCT07018050Study sitePhase 2Start 2025-09
  54. A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07312188Study sitePhase 2Start 2025-07
  55. GR1803 Injection in Patients With RRMMRecruitingNCT06952075Study sitePhase 2Start 2025-04
  56. A Study of QLS4131 in Patients With Recurrent or Refractory Multiple MyelomaNot yet recruitingNCT06500507Study sitePhase 1Start 2024-08
  57. A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.RecruitingNCT06232096Study sitePhase 1/Phase 2Start 2024-02
  58. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06375044Study sitePhase 1Start 2024-05
  59. Long-term Follow-up Registry Study of Equecabtagene Autoleucel InjectionRecruitingNCT07028970Study siteStart 2024-12
  60. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Study sitePhase 3Start 2022-11
  61. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  62. A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT05521802Study sitePhase 1/Phase 2Start 2022-11
  63. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  64. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  65. A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04634552Study sitePhase 2Start 2021-02
  66. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  67. A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06934044Study sitePhase 1Start 2025-05
  68. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  69. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  70. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  71. A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple MyelomaTerminatedNCT05590377Study sitePhase 1/Phase 2Start 2023-01
  72. A Study of QLS32015 in Patients With Recurrent or Refractory Multiple MyelomaStatus unknownNCT05920876Study sitePhase 1Start 2023-06
  73. Study of 3D189 in Patients With Hematologic MalignanciesCompletedNCT05320809Study sitePhase 1Start 2022-08
  74. BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT05376345Study sitePhase 1Start 2022-09
  75. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  76. Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantActive, not recruitingNCT05317416Study sitePhase 3Start 2022-03
  77. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  78. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Study sitePhase 2Start 2021-12
  79. A Study of TQB3820 in Patients With Hematological MalignanciesStatus unknownNCT05020639Study sitePhase 1Start 2021-08
  80. A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple MyelomaCompletedNCT05011097Study sitePhase 1Start 2021-07
  81. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05
  82. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Study sitePhase 1/Phase 2Start 2020-04
  83. A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple MyelomaCompletedNCT04121260Study sitePhase 1Start 2019-12
  84. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  85. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  86. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  87. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03
  88. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  89. Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsCompletedNCT02649790Study sitePhase 1/Phase 2Start 2016-01
  90. Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple MyelomaStatus unknownNCT02916420Study sitePhase 3Start 2016-09
  91. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07
  92. Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaCompletedNCT00689936Study sitePhase 3Start 2008-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 13 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 5.8%.

Papers led
13
2021–2025
Trials led
17
any status, ClinicalTrials.gov
Open trials led
12
recruiting or about to
Open trials as a site
8
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 2220232024: 2220242025: 552025

3 hospitals in Tianjin for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 20

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07106749

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  4. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

  5. Recruiting
    CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06355739

    Age 3 years to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  6. Recruiting
    Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06387121

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  7. Recruiting
    Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06481228

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  8. Recruiting
    Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06481241

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  9. Recruiting
    Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06608732

    Age 16 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  10. Not yet recruiting
    Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
    Phase
    Phase 1
    Started
    2026-04
    Registry
    NCT07539610

    Age 18 years to 69 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  11. Not yet recruiting
    Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07840976

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  12. Not yet recruiting
    A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07234045

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  13. Recruiting
    Phase I Study of FXS0683 in the Treatment of Blood Tumors
    Phase
    Phase 1
    Started
    2026-06
    Registry
    NCT07616089

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  14. Recruiting
    TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Registry
    NCT06481735

    Age 16 years to 70 years (registered criteria)

    Led by Chinese PLA General Hospital; 3 listed hospitals as study sitesBeijing, Tianjin

  15. Recruiting
    A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
    Phase
    Early phase 1
    Started
    2025-09
    Registry
    NCT07205315

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  16. Recruiting
    CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT06179524

    Age Not stated to 25 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  17. Recruiting
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06450067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  18. Recruiting
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05667506

    Age 3 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChongqing, Guangzhou, Hefei, Nanchang, Nanjing, Tianjin, Wuhan, Xuzhou

  19. Recruiting
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05334823

    Age 3 years to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou

  20. Recruiting
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Registry
    NCT05579132

    Age 2 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChildrenPhiladelphia chromosome & geneticsCAR-T & cell therapy
Papers it led13
  1. Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.2025Blood advancesFree full text
  2. Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 CAR T cells: a case report.2025Frontiers in immunologyFree full text
  3. Comprehensive omics-based classification system in adult patients with B-cell acute lymphoblastic leukemia.2025Molecular oncologyFree full text
  4. Total body irradiation versus chemotherapy myeloablative conditioning in B-cell acute lymphoblastic leukaemia patients with first complete remission.2025Scientific reportsFree full text
  5. Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL.2025Signal transduction and targeted therapyFree full text
  6. Effectiveness and safety of blinatumomab for pediatric B cell acute lymphoblastic leukemia with Loeffler's endocarditis.2024Annals of hematology
  7. Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia.2024Cancer letters
  8. Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease.2023British journal of haematology
  9. Functional diversification and dynamics of CAR-T cells in patients with B-ALL.2023Cell reports
  10. Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report.2022Frontiers in immunologyFree full text
  11. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.2022Hematology (Amsterdam, Netherlands)
  12. A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL.2021Blood cancer journalFree full text
  13. Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL.2021Cancer immunology, immunotherapy : CIIFree full text
Chinese-language papers (not in the count)4
  1. [How I manage relapsed/refractory B-cell acute lymphoblastic leukemia patients treated with CD19 CAR- T cells throughout whole-process management].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [The safety and efficacy of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia in children].2024Zhonghua yi xue za zhi
  3. [Safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia].2023Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsFree full text
  4. [Optimized treatment of childhood B-lineage acute lymphoblastic leukemia].2023Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsFree full text
All its trials on ClinicalTrials.gov, any status29
  1. Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingNCT07840976Lead sponsorPhase 2Start 2026-10
  2. Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic TumorsNot yet recruitingNCT07539610Lead sponsorPhase 1Start 2026-04
  3. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Lead sponsorPhase 2/Phase 3Start 2025-01
  4. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Lead sponsorPhase 3Start 2025-03
  5. A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell NeoplasmsNot yet recruitingNCT07234045Lead sponsorPhase 1Start 2025-11
  6. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Lead sponsorPhase 2/Phase 3Start 2025-03
  7. CD180 CART for Relapsed or Refractory CD180 Positive Hematologic MalignanciesRecruitingNCT07106749Lead sponsorPhase 1Start 2025-06
  8. Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.RecruitingNCT06608732Lead sponsorPhase 2Start 2024-08
  9. Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLRecruitingNCT06387121Lead sponsorPhase 2Start 2024-04
  10. Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLRecruitingNCT06481228Lead sponsorN/AStart 2024-06
  11. Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALLRecruitingNCT06481241Lead sponsorN/AStart 2024-06
  12. A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic LeukemiaTerminatedNCT05292898Lead sponsorPhase 1Start 2022-03
  13. γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)Status unknownNCT04028440Lead sponsorEarly phase 1Start 2019-10
  14. CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT04034446Lead sponsorEarly phase 1Start 2019-09
  15. CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic LeukemiaCompletedNCT02975687Lead sponsorPhase 1Start 2016-11
  16. CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+RecruitingNCT06355739Lead (inferred)N/AStart 2024-02
  17. Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic LeukemiaStatus unknownNCT01990807Lead (inferred)Phase 4Start 2012-10
  18. Phase I Study of FXS0683 in the Treatment of Blood TumorsRecruitingNCT07616089Study sitePhase 1Start 2026-06
  19. A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic AnemiaRecruitingNCT07205315Study siteEarly phase 1Start 2025-09
  20. TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALLRecruitingNCT06481735Study sitePhase 1/Phase 2Start 2025-02
  21. Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic LeukemiaRecruitingNCT06450067Study siteStart 2024-06
  22. CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLRecruitingNCT06179524Study sitePhase 2Start 2024-01
  23. A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)RecruitingNCT05667506Study sitePhase 1/Phase 2Start 2023-02
  24. A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsRecruitingNCT05334823Study sitePhase 2Start 2022-01
  25. A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)RecruitingNCT05579132Study sitePhase 1/Phase 2Start 2022-11
  26. Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)Active, not recruitingNCT06054113Study sitePhase 2Start 2024-07
  27. CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic LeukemiaStatus unknownNCT05727683Study sitePhase 1Start 2022-04
  28. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Study sitePhase 1/Phase 2Start 2021-01
  29. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT03476239Study sitePhase 3Start 2017-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 48 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 11.7%.

Papers led
48
2021–2025
Trials led
30
any status, ClinicalTrials.gov
Open trials led
9
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 9920212022: 101020222023: 141420232024: 6620242025: 992025

2 hospitals in Tianjin for aplastic anaemia63 hospitals in China for aplastic anaemia

Open trials with this hospital 10

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
    Phase
    Not given
    Started
    2026-02
    Registry
    NCT07461116

    Age not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  2. Recruiting
    Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Registry
    NCT07714512

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  3. Recruiting
    Reproductive and Mental Health of Patients With Aplastic Anemia
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06936930

    Age 18 years to 40 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  4. Recruiting
    Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT07010237

    Age 65 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  5. Recruiting
    The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Registry
    NCT07287228

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  6. Recruiting
    Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07578675

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  7. Recruiting
    Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
    Phase
    Phase 2
    Started
    2023-02
    Registry
    NCT06254560

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  8. Recruiting
    National Longitudinal Cohort of Hematological Diseases
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT04645199

    Age not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  9. Not yet recruiting
    Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07078721

    Age 18 years to 50 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  10. Not yet recruiting
    Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT06791824

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunosuppressive treatmentChildrenStem cell transplant
Departments in papersPediatrics
Papers it led48
  1. Somatic mutations and the efficacy of immunosuppressive therapy in severe/very severe aplastic anemia and transfusion-dependent nonsevere aplastic anemia.2025Annals of hematologyFree full text
  2. Assessing serum thrombopoietin for enhanced diagnosis of ITP, AA, and MDS using machine learning: A retrospective cohort study.2025Annals of hematologyFree full text
  3. The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia.2025Annals of hematologyFree full text
  4. Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia.2025Blood
  5. Targeting interleukin-2-inducible T cell kinase ameliorates immune-mediated aplastic anemia.2025Cancer immunology, immunotherapy : CIIFree full text
  6. Comparison of Hetrombopag and Eltrombopag Added to First-Line Immunosuppressive Therapy in Severe Aplastic Anemia.2025European journal of haematology
  7. Platelet transfusion refractoriness within one month post-hematopoietic stem cell transplantation does not impair survival in aplastic anemia patients after engraftment: a propensity score-matched analysis.2025Frontiers in immunologyFree full text
  8. Cost utility analysis of adult patients with severe aplastic anemia: a single-center study.2025Hematology (Amsterdam, Netherlands)
  9. Application of platelet transcriptomics for assessing treatment effectiveness and predicting long-term platelet counts recovery in aplastic anemia.2025Journal of thrombosis and haemostasis : JTH
  10. A preliminary study of roxadustat in the treatment of aplastic anemia patients with inadequate erythroid responses.2024Annals of hematologyFree full text
  11. Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients.2024Bone marrow transplantationFree full text
  12. Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia.2024Experimental hematology
  13. Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia.2024Frontiers in immunologyFree full text
  14. Encephalitozoon hellem infection after haploidentical allogeneic hematopoietic stem cell transplantation in children: a case report.2024Frontiers in immunologyFree full text
  15. Exploring strategies to optimise outcomes in hepatitis-associated aplastic anaemia patients following haematopoietic stem cell transplantation.2024Scientific reportsFree full text
  16. Low risk of relapse in aplastic anemia patients after SARS-CoV-2 omicron infection: A prospective NICHE cohort.2023American journal of hematology
  17. Mass cytometry analysis identifies T cell immune signature of aplastic anemia and predicts the response to cyclosporine.2023Annals of hematologyFree full text
  18. Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia.2023BMC medical genomicsFree full text
  19. Haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia and non-hepatitis-associated aplastic anaemia: A propensity score-matched analysis.2023British journal of haematology
  20. Phenotypic and genotypic correlation evaluation of 148 pediatric patients with Fanconi anemia in a Chinese rare disease cohort.2023Clinica chimica acta; international journal of clinical chemistry
  21. Long-term outcomes of aplastic anemia with cytogenetic abnormalities at diagnosis.2023European journal of haematology
  22. Development and validation of early death risk score model for emergency status prediction in very severe aplastic anemia.2023Frontiers in immunologyFree full text
  23. Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis-associated aplastic anemia.2023Frontiers in immunologyFree full text
  24. Association between human leukocyte antigen and immunosuppressive treatment outcomes in Chinese patients with aplastic anemia.2023Frontiers in immunologyFree full text
  25. Interleukin-10 promoter variability is associated with the susceptibility, severity, and clinical outcomes of aplasitc anemia in Han-Chinese population.2023International journal of laboratory hematology
  26. Single-cell analysis highlights a population of Th17-polarized CD4+ naïve T cells showing IL6/JAK3/STAT3 activation in pediatric severe aplastic anemia.2023Journal of autoimmunity
  27. Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia.2023Scientific reportsFree full text
  28. Application of serum Raman spectroscopy in rapid and early discrimination of aplastic anemia and myelodysplastic syndrome.2023Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  29. Impaired immunosuppressive effect of bone marrow mesenchymal stem cell-derived exosomes on T cells in aplastic anemia.2023Stem cell research & therapyFree full text
  30. Clinical characteristics and prognostic factors in intracranial hemorrhage patients with hematological diseases.2022Annals of hematologyFree full text
  31. First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years' experience.2022Annals of hematology
  32. Leptin-mediated proinflammatory bone marrow environment in acquired aplastic anemia.2022Cytokine
  33. The prognostic impact of previously infectious complications on allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia: A single-center, retrospective study.2022Frontiers in immunologyFree full text
  34. Levamisole Suppresses CD4+ T-Cell Proliferation and Antigen-Presenting Cell Activation in Aplastic Anemia by Regulating the JAK/STAT and TLR Signaling Pathways.2022Frontiers in immunologyFree full text
  35. Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors.2022Frontiers in immunologyFree full text
  36. Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia.2022Frontiers in immunologyFree full text
  37. Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia.2022Haematologica
  38. Short Stature in Patients with Diamond-Blackfan Anemia: A Cross-Sectional Study.2022The Journal of pediatrics
  39. Efficacy of anti-thymocyte globulin for platelet transfusion refractoriness in serious aplastic anemia patients.2022Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  40. PNH Clones for Aplastic Anemia with Immunosuppressive Therapy: A Systematic Review and Meta-Analysis.2021Acta haematologica
  41. Red blood cell lifespan is reduced in severe aplastic anemia and improves with response to immunosuppressive treatment.2021American journal of hematology
  42. Time and residual hematopoiesis are crucial for PNH clones escape in hepatitis-associated aplastic anemia.2021Annals of hematology
  43. Long-term outcomes of 172 children with severe aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine.2021Annals of hematology
  44. Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia.2021BMC pediatricsFree full text
  45. Successful Treatment of a 19-Month-Old Boy with Hepatitis Associated Aplastic Anemia by Infusion of Umbilical Cord-Derived Mesenchymal Stromal Cells: A Case Report.2021Cell transplantationFree full text
  46. Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia.2021Chinese medical journalFree full text
  47. Platelet/Lymphocyte ratio independently predicts the outcome of severe aplastic anemia patients treated with antithymocyte globulin.2021Revista da Associacao Medica Brasileira (1992)
  48. Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?-a systematic review and meta-analysis.2021Stem cell research & therapyFree full text
Chinese-language papers (not in the count)24
  1. [Advancements in CRISPR-Cas9 for Fanconi anemia].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [Melatonin-Mediated Inhibitory Effect on Hyperimmune Status of Acquired Aplastic Anemia].2023Zhongguo shi yan xue ye xue za zhi
  3. [Clinical characteristics of aplastic anemia patients with abnormal autoantibodies and the impact of autoantibodies on immunosuppressive therapy response].2023Zhonghua nei ke za zhi
  4. [Evaluation of the clinical manifestations of COVID-19 in patients with aplastic anemia undergoing immunosuppressive therapy: a prospective cohort study (NICHE)].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  5. [Efficacy and safety of allogeneic hematopoietic stem cell transplantation in the treatment of 28 patients with hepatitis-related aplastic anemia].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  6. [Metagenomic next-generation sequencing of plasma for the identification of bloodstream infectious pathogens in severe aplastic anemia].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  7. [The effect of on-demand glucocorticoid strategy on the occurrence and outcome of p-ALG-associated serum sickness in aplastic anemia].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  8. [Clinical analysis of 76 patients with severe aplastic anemia treated with haploid hematopoietic stem cell transplantation].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  9. [T-large granular lymphocytic leukemia presenting as aplastic anemia: a report of five cases and literature review].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  10. [Prevalence and risk factors of obesity in children with Diamond-Blackfan anemia].2022Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsFree full text
  11. Significance of paroxysmal nocturnal hemoglobinuria clone in immunosuppressive therapy for children with severe aplastic anemia.2022Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsFree full text
  12. [Avatrombopag combined with standard immunosuppressive therapy in the treatment of severe aplastic anemia with hepatic impairment in six patients].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  13. [Hematologic responses to avatrombopag switch in TPO-RA refractory aplastic anemia].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  14. [Kinetics of immune activated T cells in aplastic anemia mouse model].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  15. [Pharmacokinetic study of anti-human T-cell porcine immunoglobulin combined with cyclosporine A immunosuppressive therapy in patients with severe aplastic anemia].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  16. [Reassessing the six months prognosis of patients with severe or very severe aplastic anemia without hematological responses at three months after immunosuppressive therapy].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  17. [Bone marrow failure with body deformities].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  18. Research advances on haploidentical hematopoietic stem cell transplantation in the treatment of severe aplastic anemia in children.2021Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsFree full text
  19. [Clinical Characteristics and Prognosis Analysis of Pediatric Severe Aplastic Anemia].2021Zhongguo shi yan xue ye xue za zhi
  20. [Optimization of Mouse Model of Aplastic Anemia Induced by Pan T Lymphocytes Combined with Irradiation].2021Zhongguo shi yan xue ye xue za zhi
  21. [Relationship between Changes of Lymphocyte Subsets and Early Hematologic Response in Immunosuppressive Therapy of Severe Aplastic Anemia Patients].2021Zhongguo shi yan xue ye xue za zhi
  22. [Advances in bone marrow failure related ribosomopathies].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
  23. [Syngeneic hematopoietic stem cell transplantation for aplastic anemia].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  24. [A real-world study of 176 cases with aplastic anemia treated in outpatient].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status35
  1. Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic AnemiaRecruitingNCT07714512Lead sponsorPhase 1/Phase 2Start 2026-06
  2. Adverse Effects of ATG/ALG Therapy in Aplastic AnemiaRecruitingNCT07461116Lead sponsorStart 2026-02
  3. Reproductive and Mental Health of Patients With Aplastic AnemiaRecruitingNCT06936930Lead sponsorStart 2025-03
  4. Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRSRecruitingNCT07578675Lead sponsorStart 2025-10
  5. The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic AnemiaRecruitingNCT07287228Lead sponsorPhase 1/Phase 2Start 2025-12
  6. Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic AnemiaRecruitingNCT07010237Lead sponsorPhase 2Start 2025-02
  7. Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic AnemiaNot yet recruitingNCT07078721Lead sponsorPhase 2Start 2025-07
  8. Rituximab for Serious Aplastic Anemia With Platelet Transfusion RefractorinessRecruitingNCT06254560Lead sponsorPhase 2Start 2023-02
  9. National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199Lead sponsorStart 2020-12
  10. CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic AnemiaSuspendedNCT06622694Lead sponsorPhase 1Start 2025-06
  11. Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic AnemiaActive, not recruitingNCT06613880Lead sponsorPhase 2Start 2024-10
  12. Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic AnemiaTerminatedNCT06695741Lead sponsorPhase 2Start 2024-11
  13. Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic AnemiaStatus unknownNCT05975996Lead sponsorPhase 2Start 2023-07
  14. Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic AnemiaCompletedNCT05832216Lead sponsorPhase 1Start 2023-04
  15. Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver FunctionStatus unknownNCT05571332Lead sponsorN/AStart 2022-06
  16. Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the ElderlyStatus unknownNCT05433922Lead sponsorN/AStart 2022-06
  17. The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AAStatus unknownNCT05518331Lead sponsorN/AStart 2022-06
  18. A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte DeficiencyStatus unknownNCT05531279Lead sponsorN/AStart 2022-06
  19. Herombopag Added to Cyclosporine in Non Severe Aplastic AnemiaCompletedNCT05660785Lead sponsorPhase 2Start 2022-12
  20. Avatrombopag Combined With IST as First-line Treatment for SAAStatus unknownNCT05720234Lead sponsorPhase 2Start 2022-11
  21. Clinical Study of UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAACompletedNCT07850362Lead sponsorN/AStart 2021-09
  22. Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic AnemiaTerminatedNCT04854889Lead sponsorPhase 2Start 2021-04
  23. A Randomized, Controlled Clinical Study on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Combined With Standard Immunosuppressants in the Treatment of Children With Severe Aplastic AnemiaCompletedNCT07903649Lead sponsorPhase 2Start 2021-02
  24. A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic AnemiaCompletedNCT02203396Lead sponsorPhase 2Start 2014-08
  25. Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)Status unknownNCT01760096Lead sponsorPhase 2Start 2013-01
  26. Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal HemoglobinuriaStatus unknownNCT01642979Lead sponsorPhase 2Start 2012-07
  27. Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived)Status unknownNCT02218437Lead (inferred)Phase 4Start 2013-10
  28. Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic AnemiaStatus unknownNCT01995331Lead (inferred)Phase 4Start 2012-03
  29. Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic AnemiaStatus unknownNCT01997372Lead (inferred)Phase 4Start 2010-12
  30. Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their PatentsAvailableNCT01995305Lead (inferred)
  31. Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic AnemiaNot yet recruitingNCT06791824Study sitePhase 1/Phase 2Start 2025-03
  32. Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic AnemiaStatus unknownNCT05797623Study sitePhase 2Start 2023-04
  33. Hetrombopag or Placebo in Treatment-Naive Severe Aplastic AnemiaCompletedNCT03825744Study sitePhase 3Start 2019-03
  34. Extension Study of Hetrombopag in Severe Aplastic AnemiaStatus unknownNCT04961710Study sitePhase 3Start 2019-09
  35. A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) PatientCompletedNCT03557099Study sitePhase 1/Phase 2Start 2018-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Tianjin for beta thalassaemia157 hospitals in China for beta thalassaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    β-Thalassemia Treatment With KL003 Cell Injection
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Registry
    NCT06280378

    Age 3 years to 35 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 25 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 9.2%.

Papers led
25
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 4420212022: 7720222023: 6620232024: 3320242025: 552025

1 hospital in Tianjin for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
    Phase
    Early phase 1
    Started
    2024-01
    Registry
    NCT06238908

    Age 18 years to Not stated; men only (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  2. Recruiting
    ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
    Phase
    Phase 4
    Started
    2023-11
    Registry
    NCT05888870

    Age 14 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  3. Recruiting
    A Study of FVIII Gene Therapy for Hemophilia A
    Phase
    Early phase 1
    Started
    2022-07
    Registry
    NCT05454774

    Age 18 years to Not stated; men only (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  4. Recruiting
    Gene Therapy for Chinese Hemophilia A
    Phase
    N/A
    Started
    2021-03
    Registry
    NCT04728841

    Age 18 years to Not stated; men only (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  5. Recruiting
    National Longitudinal Cohort of Hematological Diseases
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT04645199

    Age not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  6. Recruiting
    A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07416604

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Tianjin

  7. Recruiting
    Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07545395

    Age 12 years to 65 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  8. Recruiting
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06833983

    Age 18 years to 65 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou

  9. Recruiting
    Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
    Phase
    Phase 2/Phase 3
    Started
    2024-01
    Registry
    NCT06111638

    Age 18 years to Not stated; men only (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi’an

  10. Recruiting
    A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
    Phase
    Phase 3
    Started
    2022-12
    Registry
    NCT05611801

    Age 1 year to 17 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan

  11. Recruiting
    Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
    Phase
    Phase 3
    Started
    2021-11
    Registry
    NCT05145127

    Age 1 year to 74 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led25
  1. Disease Burden and Treatment Patterns Amongst Patients with Haemophilia A in China: A Retrospective Database Analysis Study.2025Advances in therapy
  2. The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study.2025Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  3. Nationwide Survey of Laboratory Practices for Factor VIII Inhibitor Detection in China.2025Haemophilia : the official journal of the World Federation of Hemophilia
  4. The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping.2025Hematology (Amsterdam, Netherlands)
  5. Biomembrane-inspired lipid nanoparticles enhance CRISPR-Cas9 editing for hemophilia A.2025Journal of controlled release : official journal of the Controlled Release Society
  6. Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial.2024American journal of hematologyRCT
  7. Decoding the complexity of on-target integration: characterizing DNA insertions at the CRISPR-Cas9 targeted locus using nanopore sequencing.2024BMC genomics
  8. Reduced doses of emicizumab achieve good efficacy: Results from a national-wide multicentre real-world study in China.2024Haemophilia : the official journal of the World Federation of Hemophilia
  9. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia.2023Haemophilia : the official journal of the World Federation of Hemophilia
  10. Efficacy and safety of the B-domain-deleted TQG202 for on-demand treatment in moderate and severe haemophilia A patients: A multicentre, single-arm trial.2023Haemophilia : the official journal of the World Federation of Hemophilia
  11. Women and girls with haemophilia: A retrospective cohort study in China.2023Haemophilia : the official journal of the World Federation of Hemophilia
  12. Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China.2023Haemophilia : the official journal of the World Federation of Hemophilia
  13. Anti-CD38 antibody for refractory acquired hemophilia A.2023Journal of thrombosis and haemostasis : JTH
  14. Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors.2023Journal of thrombosis and haemostasis : JTH
  15. Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.2022Haemophilia : the official journal of the World Federation of HemophiliaRCT
  16. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.2022Haemophilia : the official journal of the World Federation of Hemophilia
  17. Health-related quality of life among adults with haemophilia in China: A comparison with age-matched general population.2022Haemophilia : the official journal of the World Federation of Hemophilia
  18. Haemophilia gene therapy-Update on new country initiatives.2022Haemophilia : the official journal of the World Federation of Hemophilia
  19. Demographics, clinical profile and treatment landscape of patients with haemophilia B in China.2022Haemophilia : the official journal of the World Federation of Hemophilia
  20. Modulation of Immune Reaction in Hydrodynamic Gene Therapy for Hemophilia A.2022Human gene therapy
  21. Total Knee Arthroplasty after Gene Therapy for Hemophilia B.2022The New England journal of medicine
  22. Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and real-world clinical practices.2021British journal of haematology
  23. Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up.2021British journal of haematology
  24. Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A.2021Haemophilia : the official journal of the World Federation of Hemophilia
  25. An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies.2021Haemophilia : the official journal of the World Federation of Hemophilia
Chinese-language papers (not in the count)5
  1. [How I treat acquired clotting factor deficiency].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  2. [Clinical efficacy and safety of Octocog alfa in Chinese patients with hemophilia A: One-year follow-up results from the Antihemophilic Factor Hemophilia A Outcome Database (AHEAD) study].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  3. [Keeping up with the trends and improving the hierarchical system for the diagnosis and treatment of hemophilia in China].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  4. [Recent advances in the replacement therapy for Hemophilia].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  5. [Advances in long-acting recombinant factor Ⅸ for the treatment of hemophilia B].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Earlier papers (2016–2020)19
  1. Growing success and ambitions of the Chinese edition of Haemophilia.2020Haemophilia : the official journal of the World Federation of Hemophilia
  2. Management of haemophilia patients in the COVID-19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China.2020Haemophilia : the official journal of the World Federation of Hemophilia
  3. Haemophilia care in China: Achievements in the past decade.2020Haemophilia : the official journal of the World Federation of Hemophilia
  4. Real-world analysis of haemophilia patients in China: A single centre's experience.2020Haemophilia : the official journal of the World Federation of Hemophilia
  5. Building a network for hemophilia care in China: 15 years of achievement for the Hemophilia Treatment Center Collaborative Network of China.2019Blood advances
  6. Outcome of CARE: a 6-year national registry of acquired haemophilia A in China.2019British journal of haematology
  7. Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse.2019Genome biology
  8. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.2019Haemophilia : the official journal of the World Federation of Hemophilia
  9. [How I treat hemophilia with inhibitors].2019Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  10. [HEAD-US-C quantitative ultrasound assessment scale in evaluation of joint damage in patients with moderate or severe hemophilia A received on-demand versus prophylaxis replacement therapy].2018Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  11. [A phase Ⅲ multi-center clinical trial on safety and efficacy of a domestic plasma derived factor Ⅸ for the treatment of patients with hemophilia B].2018Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  12. [Clinical application and optimization of HEAD-US quantitative ultrasound assessment scale for hemophilic arthropathy].2018Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  13. Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII.2017Scientific reports
  14. [Immune tolerance induction in a case of hemophilia B with inhibitor with prothrombin complex concentrate and rituximab].2017Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  15. [Advances in Hemophilia A inhibitors].2017Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  16. [Analysis of clinical efficacy of recombinant activated factor Ⅶ on bleeding in patients with hematologic disorders].2017Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  17. [Retrospectively analysis of the difference of bleeding frequency and hemophilic arthropathy between hemophilia A and hemophilia B patients].2017Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  18. Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high-throughput sequencing.2016Haemophilia : the official journal of the World Federation of Hemophilia
  19. [Study on risk factors and follow-up of 26 hemophilia A children with inhibitors].2016Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
All its trials on ClinicalTrials.gov, any status47
  1. Safety and Efficacy Study of NGGT003 in Hemophilia A PatientsRecruitingNCT06238908Lead sponsorEarly phase 1Start 2024-01
  2. ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer InhibitorRecruitingNCT05888870Lead sponsorPhase 4Start 2023-11
  3. A Study of FVIII Gene Therapy for Hemophilia ARecruitingNCT05454774Lead sponsorEarly phase 1Start 2022-07
  4. Gene Therapy for Chinese Hemophilia ARecruitingNCT04728841Lead sponsorN/AStart 2021-03
  5. National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199Lead sponsorStart 2020-12
  6. A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia ANot yet recruitingNCT07788469Lead sponsorN/AStart 2026-10
  7. The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.Status unknownNCT05523128Lead sponsorN/AStart 2022-09
  8. Data Registry in Chinese Hemophilia A and B PatientsCompletedNCT07101224Lead sponsorStart 2017-05
  9. Safety of KN057 Prophylaxis in Patients With Haemophilia A or BRecruitingNCT07545395Study sitePhase 3Start 2026-03
  10. A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia ARecruitingNCT07416604Study sitePhase 3Start 2026-04
  11. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia ARecruitingNCT06833983Study sitePhase 3Start 2025-03
  12. Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy DrugsRecruitingNCT06111638Study sitePhase 2/Phase 3Start 2024-01
  13. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Study sitePhase 3Start 2022-12
  14. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Study sitePhase 3Start 2021-11
  15. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06
  16. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04
  17. Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With InhibitorsActive, not recruitingNCT06312475Study sitePhase 3Start 2024-01
  18. A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia AActive, not recruitingNCT06297655Study sitePhase 3Start 2024-11
  19. Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsActive, not recruitingNCT06569108Study sitePhase 3Start 2024-04
  20. An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII DeficiencyRecruitingNCT07644832Study sitePhase 1/Phase 2Start 2024-05
  21. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Study sitePhase 3Start 2023-03
  22. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia AActive, not recruitingNCT05685238Study sitePhase 3Start 2023-02
  23. SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand TreatmentCompletedNCT06010953Study sitePhase 1/Phase 2Start 2023-10
  24. To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia AActive, not recruitingNCT07548411Study sitePhase 1/Phase 2Start 2023-07
  25. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  26. A Phase I of SS109 in Hemophilia A or and B With InhibitorsCompletedNCT05651061Study sitePhase 1Start 2022-12
  27. A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionCompletedNCT05265286Study sitePhase 2Start 2022-04
  28. Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With InhibitorStatus unknownNCT05487976Study sitePhase 3Start 2022-04
  29. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without InhibitorsCompletedNCT05306418Study sitePhase 3Start 2022-04
  30. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)CompletedNCT05082116Study sitePhase 3Start 2021-09
  31. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  32. A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionCompletedNCT04864743Study sitePhase 1Start 2021-06
  33. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsCompletedNCT05053139Study sitePhase 3Start 2021-12
  34. Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BCompletedNCT03938792Study sitePhase 3Start 2020-03
  35. A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With InhibitorCompletedNCT04747964Study sitePhase 1Start 2020-01
  36. Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.Status unknownNCT04768699Study sitePhase 1Start 2020-12
  37. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  38. Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.Status unknownNCT03947567Study sitePhase 4Start 2019-07
  39. A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionStatus unknownNCT03747653Study siteStart 2019-03
  40. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownNCT04061109Study sitePhase 3Start 2019-05
  41. Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownNCT04060836Study sitePhase 1Start 2019-05
  42. Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia ACompletedNCT03815318Study sitePhase 3Start 2019-01
  43. Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsCompletedNCT03315455Study sitePhase 3Start 2018-04
  44. Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia AStatus unknownNCT02930317Study sitePhase 3Start 2016-08
  45. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia ACompletedNCT02492984Study sitePhase 4Start 2015-04
  46. A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care TreatmentCompletedNCT02476942Study siteStart 2015-05
  47. ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)CompletedNCT02078427Study siteStart 2011-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Tianjin for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)2
  1. [Clinical characteristics of 83 patients with thrombotic thrombocytopenic purpura].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  2. [Advances in the treatment of thrombotic thrombocytopenic purpura].2019Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 3 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 4.4%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 002025

1 hospital in Tianjin for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Tianjin for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Mitochondrial respiratory complex IV deficiency recapitulates amyotrophic lateral sclerosis.2025Nature neuroscience
All its trials on ClinicalTrials.gov, any status1
  1. Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Enrolling by invitationNCT07539662Lead sponsorN/AStart 2025-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

4 hospitals in Tianjin for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

3 hospitals in Tianjin for Gaucher disease41 hospitals in China for Gaucher disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06818838

    Age 18 years to 60 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Taiyuan, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Clinical features and genetic manifestations of two families with Gaucher's disease].2019Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
All its trials on ClinicalTrials.gov, any status2
  1. A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher DiseaseRecruitingNCT06818838Study sitePhase 1/Phase 2Start 2024-07
  2. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseCompletedNCT05529992Study sitePhase 3Start 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Tianjin for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中国医学科学院血液病医院(血液学研究所)

Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC

天津

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Yunnan Blood Disease Hospital; Insitute of Hematology & Blood Disarses Hospital; Blood Disease Hospital; Blood Diseases Hospital; Hematology and Blood Diseases Hospital; Institute of Hematology & Blood Diseases Hospital; Institute of Hematology and Blood Diseases Hospital; 中国医学科学院血液病医院

Suggest a correctionDownload the data